RxDoctor Payments Data

Mark Hofmeyer, MD

Advanced Heart Failure and Transplant Cardiology · Washington, DCNPI 1194926071

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Nuwellis, Inc. accounts for 72.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $8,183 and has fallen 86.5% since, to $1,108 in 2025.

$10,481in general payments, 2019–2025

Across 73 payments — averaging $143.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nuwellis, Inc.$8K
  • Abbott$1K
  • Abiomed$171
  • Boehringer Ingelheim$155
  • Merck$151
  • Novartis$137
  • plus $755 from 13 others
$35,368in research payments, 2019–2025

Across 9 payments — averaging $3929.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Array Biopharma Inc$21K
  • E.r. Squibb & Sons, L.L.C.$14K

What the payments were for

  • Speaking & faculty fees$5,60053%
  • Travel & lodging$2,03419%
  • Food & beverage$2,84727%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$137,889
Medicare patients
227
Services billed
1,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis27$597,696
EntrestoSacubitril/Valsartan166$257,084
JardianceEmpagliflozin63$97,041
FarxigaDapagliflozin Propanediol64$71,996
EliquisApixaban39$52,565
Rosuvastatin Calcium59$3,488
Tacrolimus13$1,683
Carvedilol107$1,338
Mycophenolate Mofetil13$946
Spironolactone117$928
Metoprolol Succinate46$909
Hydralazine Hcl36$775
Losartan Potassium59$549
Colchicine14$534
Sildenafil Citrate11$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$57$650,26166 claims
NovartisEntresto$137$257,084166 claims
Boehringer IngelheimJardiance$155$97,04163 claims
AstraZenecaFarxiga$46$71,99664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →